PCVX
VaxcyteCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
+
Peers tracked
11
U.S. public peers
Grade Position
In line
vs peer average
PCVX vs peer average
54/100
PCVX vs. peer average (C vs. C)
Grade spread
B 2 · C 4 · D 5
Graded peers loaded
Coverage
11 graded
100% of tracked
Peer overview
MRK is the first available peer comparator.
Merck is the clearest direct operating comparator because VAX-31 is being positioned against CAPVAXIVE in adult pneumococcal vaccination, making competitive immunogenicity, serotype breadth and safety central to any eventual commercial case. [#10-K-2026-02-24]
✓Peer source comes from the stored AI memo or peer model
✓Grades and factor rows use RankAlpha API data when available
✓Missing peer scores remain blank instead of being estimated
✓Side-by-side comparison keeps the data contract visible
PCVX
Vaxcyte
MRK
Merck
Grade
C
C
Momentum
54
41
Value
41
65
Sentiment
62
44
Setup Bias
Net —
-
Market Cap
-
-
Posture
Mixed
Mixed
Grade position vs MRK
PCVX / MRK
Grade Position
In line
PCVX vs. peer average (C vs. C)
54/100
Momentum
54
PCVXValue
41
MRKSentiment
62
PCVXRotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.
Rank
Ticker
Company
Grade
Grade score
vs PCVX
MRK is the first peer returned for this comparison set.